PTCH1 and neoplasm: Similarly, combining LDE-225 with the PI3K class I inhibitor NVP-BKM120 or the dual PI3K/mTOR inhibitor NVP-BEZ235 has markedly delayed the development of resistance in MB tumours derived from PTCH+ /− p53−/− mice [154].